TY - JOUR
T1 - Clinical trial update on shockwave therapy and future of erectile function restoration
AU - Patel, Premal
AU - Huang, Chun
AU - Molina, Manuel
AU - Ramasamy, Ranjith
N1 - Publisher Copyright:
© 2019, Springer Nature Limited.
PY - 2019/5/1
Y1 - 2019/5/1
N2 - Our interim analysis of a phase II clinical trial on low-intensity extracorporeal shockwave therapy (Li-ESWT) for men with erectile dysfunction (ED) has demonstrated it is safe with no reported adverse outcomes. Interim analysis has demonstrated Sexual Encounter Profile 3 (ability to maintain erection till completion) was achieved in 60% of men prior to Li-ESWT, which increased to 90% after treatment. Nevertheless, limitations of our clinical trial include the lack of a sham arm and our inability to exclude men with psychogenic ED. We have begun recruitment of our phase III clinical trial that will allow assessment of treatment efficacy against a sham control arm. There exists substantial interest in the use of restorative therapies (i.e., Li-ESWT, stem cells, and platelet rich plasma) for men with ED with the potential to combine therapies to potentially lead to an augmented response.
AB - Our interim analysis of a phase II clinical trial on low-intensity extracorporeal shockwave therapy (Li-ESWT) for men with erectile dysfunction (ED) has demonstrated it is safe with no reported adverse outcomes. Interim analysis has demonstrated Sexual Encounter Profile 3 (ability to maintain erection till completion) was achieved in 60% of men prior to Li-ESWT, which increased to 90% after treatment. Nevertheless, limitations of our clinical trial include the lack of a sham arm and our inability to exclude men with psychogenic ED. We have begun recruitment of our phase III clinical trial that will allow assessment of treatment efficacy against a sham control arm. There exists substantial interest in the use of restorative therapies (i.e., Li-ESWT, stem cells, and platelet rich plasma) for men with ED with the potential to combine therapies to potentially lead to an augmented response.
UR - http://www.scopus.com/inward/record.url?scp=85060530389&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85060530389&partnerID=8YFLogxK
U2 - 10.1038/s41443-019-0115-1
DO - 10.1038/s41443-019-0115-1
M3 - Comment/debate
C2 - 30670840
AN - SCOPUS:85060530389
VL - 31
SP - 206
EP - 208
JO - International Journal of Impotence Research
JF - International Journal of Impotence Research
SN - 0955-9930
IS - 3
ER -